Ovid Therapeutics Inc. (NASDAQ: OVID) shares are 40.72% up in the year-to-date (YTD) period and have moved 2.64% or $0.15 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +224.44% lower. Comparatively, the stock is -37.87% down YTD and 9.36% over the trailing 3-month period. If we look at the shorter duration, its week performance is -23.71% and -11.52% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
On April 20, 2018, Ladenburg Thalmann recommended the OVID stock is a Buy, while earlier, RBC Capital Mkts had Initiated the stock as a Outperform on September 04, 2019. 7 analysts offering the recommendations for the stock have a consensus rating of 1.60 to suggest that the OVID stock is a “Strong Buy. 0 of the 7 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 7 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $5.84. The forecasts give the Ovid Therapeutics Inc. stock a price target range of $21.00 on the higher side while at least one analyst think the stock could plunge to a low of $10.00. The two limits represent an upside potential of 72.19% or 41.6%.
Analysts estimate the earnings to decrease -13.90% in the current quarter to -$0.36, up from the -$0.43 reported in the same quarter a year ago. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.47 and -$0.3. Wall Street estimates earnings per share to be at an average of -$1.5 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 1 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 60,000 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
The 10% Owner had earlier bought another 2,000,000 OVID shares valued at $5.0 million on Oct 08. The shares were bought at $2.50 per share.
Collier Creek Holdings (NYSE:CCH), on the other hand, is trading around $16.34 with a market cap of $718.96M and analyst research firms have a positive stance on its shares.
Let us briefly look at the Collier Creek Holdings (CCH) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
CCH’s operating expenses over the recent quarter were at -$0.38 million. This represented a 169.06% of the company’s total revenues which amounted $0.56 million. With this in place, we can see that the company’s diluted EPS declined -$0.01 on the year-over-year period, growing to $0.04 as given in the last earnings report.
The company’s free cash flow for the quarter was -$0.27 million.
Investors are also buoyed by the number of investors in a company, with Collier Creek Holdings having a total of 53 institutions that hold shares in the company. The top two institutional holders are BAMCO Inc. with over 4.3 million shares worth more than $58.91 million. As of Jun 29, 2020, BAMCO Inc. held 9.77% of shares outstanding.
The other major institutional holder is Morgan Stanley, with the investment firm holding over 3.48 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $47.64 million and represent 7.90% of shares outstanding.